<DOC>
	<DOCNO>NCT02265289</DOCNO>
	<brief_summary>To assess influence 75 mg Clopidogrel pharmacodynamics safety 30 mg Lefradafiban tid</brief_summary>
	<brief_title>Influence Clopidogrel Pharmacodynamics Safety Fradafiban Healthy Male Subjects</brief_title>
	<detailed_description />
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<criteria>Written inform consent accordance good clinical practice ( GCP ) local legislation Healthy male subject Age ≥ 18 ≤ 45 year Broca ≥ 20 % ≤ + 20 % Any finding medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance History current gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological , hormonal disorder Diseases central nervous system ( epilepsy ) psychiatric disorder Chronic relevant acute infection History Allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Any bleeding disorder include prolonged habitual bleeding Other hematologic disease Cerebral bleeding ( e.g . car accident Commotio cerebri Intake drug long halflife ( &gt; 24 hour ) within 1 month prior administration Use drug might influence result trial within 10 day prior administration trial Participation another trial investigational drug within 2 month prior administration trial Smoker ( &gt; 10 cigarette 3 cigar 3 pipes/day ) inability refrain smoke study day Alcohol abuse ( &gt; 60 g/day ) Drug abuse Blood donation within 1 month prior administration trial Excessive physical activity within 5 day prior administration trial Any laboratory value outside clinically accept reference range History familial bleeding disorder Thrombocytes &lt; 150000/µl</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>